下载 Oncology Nursing Drug Handbook - v3.5.13

应用和Medical PG, FMGE Preparation - PrepLadder, Inject App, Dexcom G6, Jan Aushadhi Sugam (BPPI), iDentist Dental practice management, Pacify一样好，Oncology Nursing Drug Handbook - v3.5.13也很多，是类型医疗中最出色的应用之一。

由Skyscape Medpresso Inc开发，Oncology Nursing Drug Handbook - v3.5.13至少需要Android版本Android 5.0+。因此，如有必要，您必须更新手机。

Oncology Nursing Drug Handbook - v3.5.13 APK的最新版本为3.5.13，发行日期为2020-06-25，大小为8.4 MB。

有关1000下载的统计信息可从Google Play获得。您可以根据需要更新已单独下载或安装在Android设备上的应用。更新您的应用可以为您提供更多功能。您可以访问最新功能并提高安全性和应用程序的稳定性。

由于并非所有游戏或应用程序都兼容所有手机。并且游戏或应用程序不适用于您的设备，因此取决于Android OS版本，屏幕分辨率或Google Play允许访问的国家/地区。因此，通过APK4Share，您可以轻松下载APK文件，不受这些限制。

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity